BENLYSTA Patient

BE CONFIDENT
IN COVERAGE
FOR BENLYSTA

See how the
formulary coverage
for BENLYSTA
compares to another FDA-approved biologic for lupus.

BENLYSTA COVERAGE IN LOCAL PLANS

A lupus patient

See how BENLYSTA coverage compares with other therapies in the area

Plans BENLYSTA IV Saphnelo

* “Unknown” means the product is not listed on the plan’s formulary and coverage cannot be determined. An exception process may be available for coverage determination.
Trademarks are the property of their respective owners.

Source: Managed Markets Insight & Technology, LLC (MMIT), database as of .

What you need to know about this formulary information:
Formulary status may vary and is subject to change. Formulary comparisons do not imply comparable indications, safety, or efficacy. This is not a guarantee of partial or full coverage or payment. Consumers may be responsible for varying out-of-pocket costs based on an individual’s plan and its benefit design. Each plan administrator determines actual benefits and out-of-pocket costs per its plan’s policies. Verify coverage with plan sponsor or Centers for Medicare & Medicaid Services. Medicare Part D patients may obtain coverage for products not otherwise covered via the medical necessity process. GSK does not endorse individual plans.

United Health Care Specific Statements
Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of GSK. Communication only to Providers — not approved for Prescription Drug Plan member distribution.

MORE THAN 95% OF PATIENTS WITH LUPUS AND LUPUS NEPHRITIS NATIONWIDE HAVE COVERAGE FOR BENLYSTA AUTOINJECTOR AND IV*

Source: Managed Markets Insights & Technology (MMIT), database as of July 2022.
* Covered under a patient's medical benefit or pharmacy benefit. Covered means any potential for reimbursement from a health plan and may include step edits, prior authorizations, and other restrictions based on an analysis of formal coverage policies. Patients reflects the number of lives within a plan, as determined by MMIT. Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety. Verify coverage with the plan sponsor.

Pay as little as

† The BENLYSTA Co-Pay Program helps eligible commercially insured patients with their out-of-pocket costs for BENLYSTA up to $15,000 for 12 months. Eligibility for the BENLYSTA Co-Pay Program must be determined by the GSK Co-Pay Program. Eligibility restrictions and program maximums apply. Visit www.gskcopayprograms.com for complete Program Terms and Conditions.

Patients may
pay as little
as $0
for
BENLYSTA*

BENLYSTA Patient
BENLYSTA Patient

* The BENLYSTA Co-Pay Program helps eligible commercially insured patients with their out-of-pocket costs for BENLYSTA up to $15,000 for 12 months. Eligibility for the BENLYSTA Co-Pay Program must be determined by the GSK Co-Pay Program. Eligibility restrictions and program maximums apply. Visit www.gskcopayprograms.com for complete Program Terms and Conditions.